Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma: oncogenic drivers and the immune system.
Karachaliou N, Pilotto S, Teixidó C, Viteri S, González-Cao M, Riso A, Morales-Espinosa D, Molina MA, Chaib I, Santarpia M, Richardet E, Bria E, Rosell R. Karachaliou N, et al. Among authors: bria e. Ann Transl Med. 2015 Oct;3(18):265. doi: 10.3978/j.issn.2305-5839.2015.08.06. Ann Transl Med. 2015. PMID: 26605311 Free PMC article. Review.
DNA repair by ERCC1 in non-small-cell lung cancer.
Cecere F, Bria E, Rosell R. Cecere F, et al. Among authors: bria e. N Engl J Med. 2006 Dec 14;355(24):2590-1; author reply 2591. doi: 10.1056/NEJMc062783. N Engl J Med. 2006. PMID: 17167144 No abstract available.
Sorafenib for lung cancer: is the "Battle" still open?
Bria E, Pilotto S, Tortora G. Bria E, et al. Expert Opin Investig Drugs. 2012 Oct;21(10):1445-8. doi: 10.1517/13543784.2012.707191. Epub 2012 Jul 16. Expert Opin Investig Drugs. 2012. PMID: 22799503
Clinical meta-analyses of targeted therapies in adenocarcinoma.
Bria E, Bonomi M, Pilotto S, Massari F, Novello S, Levra MG, Tortora G, Scagliotti G. Bria E, et al. Target Oncol. 2013 Mar;8(1):35-45. doi: 10.1007/s11523-013-0262-0. Epub 2013 Jan 25. Target Oncol. 2013. PMID: 23354875 Review.
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E. Pilotto S, et al. Among authors: bria e. Expert Opin Pharmacother. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9. Expert Opin Pharmacother. 2013. PMID: 23472711 Review.
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.
Pilotto S, Di Maio M, Peretti U, Kinspergher S, Brunelli M, Massari F, Sperduti I, Giannarelli D, De Marinis F, Tortora G, Bria E. Pilotto S, et al. Among authors: bria e. Crit Rev Oncol Hematol. 2014 May;90(2):135-45. doi: 10.1016/j.critrevonc.2013.11.005. Epub 2013 Dec 1. Crit Rev Oncol Hematol. 2014. PMID: 24332915 Review.
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Pilotto S, Bria E, Peretti U, Massari F, Garassino M, Pelosi G, Tortora G. Pilotto S, et al. Among authors: bria e. J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37. J Thorac Oncol. 2013. PMID: 24389444 Free article. No abstract available.
385 results